Valneva outlines €170M-€180M sales target for 2025 with focus on IXCHIQ and Lyme vaccine developments
Valneva anticipates total product sales of €170 million to €180 million and total revenues of €180 million to €190 million for 2025, driven by increased IXCHIQ sales and growth in IXIARO and DUKORAL.
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private ...
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...